Skip to main content

Table 3 Subgroup analysis

From: Diagnostic accuracy of cardiovascular magnetic resonance imaging of right ventricular morphology and function in the assessment of suspected pulmonary hypertension results from the ASPIRE registry

 

Gp 1 IPAH n = 28

Gp 1 PAH-CTD n = 39

Gp 2 PH-LHD n = 21

Gp 3 RESP n = 29

Gp 4 CTEPH n = 59

Demographics and RHC

Age (yrs)

53 ± 17¶, +, §, ƒ

67 ± 9#

74 ± 9#

67 ± 12#

64 ± 14#

mPAP (mmHg)

54 ± 13¶, +, §

40 ± 13#, ƒ

35 ± 8#, ƒ

39 ± 8#, ƒ

49 ± 10¶, +, §

PCWP (mmHg)

11 ± 3+

11 ± 4+

21 ± 4#, ¶, §, ƒ

12 ± 4+

12 ± 5+

mRAP (mmHg)

11 ± 5

9 ± 5+

14 ± 5¶, §

9 ± 4+

12 ± 6

CO (L.min)

4.6 ± 1.4+

5.2 ± 1.6

6.2 ± 1.7#, ƒ

5.3 ± 1.3

4.8 ± 1.5+

CI (L.min.m-2)

2.5 ± 0.7¶, +

3.1 ± 0.7#, ƒ

3.4 ± 0.8#, ƒ

3.0 ± 0.6

2.5 ± 0.7¶, +

PVR (dyn.s.cm-5)

876 ± 439¶, +, §

484 ± 337#, ƒ, +

183 ± 87¶, #, ƒ,

428 ± 206#, ƒ

736 ± 373¶, +, §

CMR

RVEDVI (ml/m2)

119 ± 47

82 ± 27+, ƒ

91 ± 38

96 ± 33

108 ± 41

VMI (ratio)

1.0 ± 0.4¶, +, §

0.6 ± 0.4#, ƒ, +

0.3 ± 0.1#, ƒ, ¶

0.6 ± 0.2#, ƒ

0.8 ± 3.1¶, +, §

RV mass index (g/m2)

50 ± 19¶, +, §

27 ± 14#, ƒ

22 ± 11#, ƒ

32 ± 11#, ƒ

43 ± 16¶, +, §

Late gadolinium enhancement ratio and %

21/22 (95%)+

20/28 (77%)

4/15 (27%)#, ƒ

19/20 (95%)

38/39 (97%)+

RVEF (%)

23 ± 15

32 ± 16 ƒ

32 ± 10 ƒ

24 ± 15

21 ± 12¶, +

RVSVI (ml/m2)

26 ± 21

24 ± 14

29 ± 13

22 ± 13

21 ± 11

TAPSE (cm)

1.5 ± 0.5

1.6 ± 0.7

2.0 ± 0.6§, ƒ

1.4 ± 0.7+

1.2 ± 0.5+

sEI (ratio)

2.2 ± 0.6¶, +, §, ƒ

1.4 ± 0.4#

1.2 ± 0.2#, ƒ

1.3 ± 0.3#, ƒ

1.6 ± 0.5#,+, §

dEI (ratio)

1.5 ± 0.4¶, +, §, ƒ

1.3 ± 0.2#

1.2 ± 0.2#

1.1 ± 0.1#

1.3 ± 0.3#

Average velocity (cm/s)

7.0 ± 3.0

10.0 ± 3.7 ƒ

9.1 ± 3.4

7.4 ± 3.4

5.9 ± 2.5

Retrograde flow (L/min/m2)

0.5 ± 0.3

0.4 ± 0.3

0.5 ± 0.3

0.4 ± 0.2

0.5 ± 0.3

PA relative area change (%)

6 ± 5+

9 ± 6

13 ± 10#, ƒ

8.2 ± 6.0

6.5 ± 4.0+

Systolic PA area (cm2)

9.4 ± 1.8

9.0 ± 2.1

9.0 ± 2.2

9.1 ± 1.9

9.9 ± 2.2

Diastolic PA area (cm2)

8.9 ± 1.8

8.1 ± 2.1

7.8 ± 2.0

8.2 ± 2.0

9.2 ± 2.0

  1. Mean ± standard deviation presented.
  2. #: P < 0.05 in comparison to group 1, idiopathic pulmonary arterial hypertension (IPAH).
  3. ¶:P < 0.05 in comparison to group 2, pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD).
  4. +: P < 0.05 in comparison to group 3, pulmonary hypertension owing to left heart disease (PH-LHD).
  5. §: P < 0.05 in comparison to group 4, pulmonary hypertension associated with lung disesae (PH-RESP).
  6. ƒ: P < 0.05 in comparison to group 1, chronic thromboembolic pulmonary hypertension (CTEPH).